Genetic spectrum and treatment implications of maturity-onset diabetes of the young in the eastern Black Sea region of Türkiye: a combined adult and pediatric cohort of 296 patients with identification of rare and novel variants.

Authors

Çağrı Doğan, Burak Andaç, Mehtap Navdar Başaran, Yasemin Emür Günay, Mustafa Tarık Alay, Aysel Kalaycı

Published in

Molecular biology reports. Volume 53. Issue 1. Jul 18, 2026. Epub Jul 18, 2026.

Abstract

Maturity-onset diabetes of the young (MODY) is a clinically and genetically heterogeneous group of monogenic diabetes subtypes that is frequently misdiagnosed as type 1 or type 2 diabetes, and accurate genetic diagnosis enables a precision-medicine treatment approach. Regional Turkish data are limited, and previous Turkish series have been pediatric only. We characterized the genetic spectrum and therapeutic consequences of next-generation sequencing (NGS)-based MODY testing in a combined adult-and-pediatric cohort from the eastern Black Sea region of Türkiye.
We retrospectively analyzed 296 consecutive patients with clinically suspected MODY referred between January 2022 and June 2025. A targeted NGS panel covering 14 MODY genes was applied, variants were classified per 2015 ACMG/AMP criteria, and treatment changes attributable to the genetic diagnosis were extracted from medical records. Pathogenic or likely pathogenic (P/LP) variants were identified in 43 of 296 patients (14.5%); diagnostic yield rose to 26.0% with variants of uncertain significance included. GCK-MODY accounted for 72.1% of P/LP findings, with a recurrent frameshift c.1256del p.(Phe419SerfsTer12) across nine apparently unrelated families consistent with a regional founder allele. Rare subtypes included MODY4 (PDX1), MODY6 (NEUROD1), MODY8 (CEL), MODY10 (INS), MODY12 (ABCC8) and MODY13 (KCNJ11). The genetic diagnosis directly modified pharmacological therapy in 14 patients, including insulin discontinuation in three KATP-channel MODY and one INS-MODY case.
NGS-based MODY testing yields actionable findings in approximately one in seven clinically selected patients in this region and supports inclusion of MODY testing in routine endocrinology practice.

PMID:
42470517
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.